The University of North Carolina at Chapel Hill has been ranked 18th among U.S. universities in the inaugural Cure Innovation Index , a comprehensive new assessment measuring how effectively leading biomedical research institutions translate scientific discovery into real-world medical impact.
The Index evaluates 303 institutions nationwide and is the first ranking system designed specifically to measure not only research output, but also entrepreneurial readiness and the ability to convert discoveries into clinical and commercial applications.
UNC-Chapel Hill placed in the upper tier across all three measured domains – research capabilities, entrepreneurial readiness, and market translation – underscoring the university’s balanced strength across the full biomedical innovation pipeline.
The Index draws on more than a dozen federal and commercial datasets, an institutional audit, and survey responses from more than 3,000 biomedical researchers, industry leaders, and experts. It also incorporates findings from a nationwide survey of 3,395 U.S. researchers examining barriers to commercialization, including gaps in technology transfer support, limited access to early-stage funding, and insufficient commercialization training.
Contributing factors to Carolina’s high ranking include its Clinical and Translational Science Award program, faculty-led clinical trials, dual-degree training pathways such as MSTP and MD/MBA programs, and an entrepreneurship support system featuring an incubator, entrepreneur-in-residence program, and biomedical entrepreneurship training.
The ranking underscores UNC-Chapel Hill’s position as a leading national research university with growing strength in translational science and biomedical entrepreneurship.